BridgeBio Pharma
BBIO
164 hedge funds and large institutions have $1.28B invested in BridgeBio Pharma in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 59 increasing their positions, 59 reducing their positions, and 26 closing their positions.
156% more call options, than puts
Call options by funds: $9.02M | Put options by funds: $3.53M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 59
1.99% less ownership
Funds ownership: 97.08% → 95.09% (-2%)
8% less funds holding
Funds holding: 178 → 164 (-14)
12% less capital invested
Capital invested by funds: $1.45B → $1.28B (-$179M)
35% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$14.6M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$6.51M |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$4.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.94M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$3.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$17.9M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$11.2M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$6.66M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6.24M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$4.82M |
BBIO Hedge Fund Activity: Q2 2022 in Review
164 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q2 2022, worth a combined $1.28B — down 12% from $1.45B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of BBIO and 17 opened new positions — a net loss of 9 holders — while 59 trimmed existing stakes and 59 added.
The largest buyer was State Street, adding an estimated $14.6M. The largest seller was Perceptive Advisors, cutting an estimated $17.9M.
- 164 institutional investors held BridgeBio Pharma (BBIO) as of Q2 2022, down from 178 in Q1 2022.
- Funds reported $1.28B of BridgeBio Pharma stock for Q2 2022, down 12% quarter-over-quarter.
- 17 funds opened new BridgeBio Pharma positions in Q2 2022 and 26 closed out, a net change of -9 holders.
- The largest BridgeBio Pharma buyer in Q2 2022 was State Street, an estimated $14.6M added.
- The largest BridgeBio Pharma seller in Q2 2022 was Perceptive Advisors, an estimated $17.9M sold.
Based on aggregated 13F filings for Q2 2022.